Literature DB >> 6270012

EBV infection of mitogen-stimulated human B lymphocytes.

L Einhorn, E Klein.   

Abstract

B lymphocytes from human blood were treated with the mitogen Protein A (Staph, aureus), which induces DNA synthesis in, as well as differeniation of, the B lymphocytes. The cells were subsequently exposed to Epstein-Barr virus (EBV). EBV-infected and mitogen-stimulated cells were detected simultaneously, by using a combination of immunofluorescence (for EBNA) and autoradiography (for DNA-synthesis). In the initial phase (1-2 days) after addition of the mitogen, stimulated cells were as susceptible to infection as resting cells. Thereafter, their susceptibility decreased. This suggests that, although initiation of DNA-synthesis does not seem to limit sensitivity to the viral infection, differentiation of the B cells might do so. The intensity and pattern of EBNA-staining in prestimulated cells different from that of the controls.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6270012     DOI: 10.1002/ijc.2910270209

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Synergistic activation of cells by Epstein-Barr virus and B-cell growth factor.

Authors:  L M Hutt-Fletcher
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

2.  Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Authors:  Javier G Ogembo; Lakshmi Kannan; Ionita Ghiran; Anne Nicholson-Weller; Robert W Finberg; George C Tsokos; Joyce D Fingeroth
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

3.  Frequency of B-lymphocyte transformation by Epstein-Barr virus decreases with entry into the cell cycle.

Authors:  A J Roome; C L Reading
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

4.  Epstein-Barr virus susceptibility of normal human B lymphocyte populations.

Authors:  P Aman; B Ehlin-Henriksson; G Klein
Journal:  J Exp Med       Date:  1984-01-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.